Complex peptides, Tight timelines: How one manufacturer keeps pace with peptide innovation 

Unlock On-Demand Access!

On March 19, Oliver Reimann (Head of Sales, Marketing & BD at Intavis Peptide Services) walked through how his team handles complex peptide sequences under manufacturing pressure — from choosing which platform to run a difficult sequence on, to the chemistry adjustments that make the difference between a crude you can work with and one you have to restart.

The recording is available now. Here's what it covers:

• How Intavis routes sequences across synthesis platforms based on complexity — and what instrumentation features matter beyond throughput when timelines are fixed, and purity isn't flexible.
• The manufacturing realities of neoantigen cancer vaccine production: patient-specific sequences, a six-week delivery window, and the practical strategies Intavis uses to protect that timeline.
• A side-by-side data point: a 28-mer challenging neoantigen sequence doubled in crude purity on PurePep® Chorus with heated coupling. Same sequence, different instrument capability.